Results from the randomized, double-blind, sham-controlled TRANSFORM-AD study published in the Journal of Alzheimer's Disease, a recognized international peer-reviewed journal Statistically significant improvement in sleep quality versus sham (p < 0.001) with no serious adverse events; authors describe the study as the first to evaluate high-intensity stimulation for neuropsychiatric symptoms in Alzheimer's disease HOUSTON, TX, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq:
Nexalin Technology (NXL) stock surged 80% on massive volume following a 10-year South American distribution and manufacturing deal.
Gainers Nexalin Technology (NASDAQ:NXL) shares increased by 77.8% to $7.61 during Thursday's regular session. The company's market cap stands at $3.5 million. Stablecoin Development (AMEX:SDEV) stock rose
The 10-year exclusive agreement covers seven countries and includes an initial binding device order, a Brazilian clinical pilot and a framework for locally manufactured devices and recurring electrode royalties. Key Investor TakeawaysNexalin Technology (NASDAQ:NXL) signed a definitive exclusive South America distribution agreement with Inovanexa Medical Technologies covering Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela.
Agreement establishes an initial 100-device commercialization program for the ANVISA-approved Nexalin Sync™ across seven countries and more than 300 million people, with a structured pricing framework and a mechanism for larger strategic transactions with government and private-sector customers Agreement establishes a 10-year commercial framework covering Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela, anchored by an initial 100-device commercialization program and minimum re
Detailed price information for Nexalin Technology Inc (NXL-Q) from The Globe and Mail including charting and trades.
ORLANDO, FL / ACCESS Newswire / September 11, 2026 / RedChip Companies will air interviews with Anixa Biosciences Inc. (NASDAQ:ANIX) and Nexalin Technology Inc.
Further analysis of ADAS-Cog data from the Company’s randomized, sham-controlled clinical trial — previously published in the Journal of Alzheimer’s Disease and in Radiology — identifies specific improvements in cognitive domains associated with memory in Alzheimer’s patients One half of evaluable active-arm participants achieved a clinically meaningful improvement of four or more points on the ADAS-Cog, with domain-level gains in comprehension, memory and language function still evident three m
Detailed price information for Nexalin Technology Inc (NXL-Q) from The Globe and Mail including charting and trades.
HOUSTON, TX, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), announces that its board of directors has approved a 1-for-30 reverse stock split of the Company’s common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios. The reverse stock split will become effectiv
Detailed price information for Nexalin Technology Inc (NXL-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.